Navigation Links
FDA Approves Ranexa(R) for First Line Anti Anginal Use and Adds New Claims for Reduction of Ventricular Arrhythmias, Bradycardia, New Atrial Fibrillation and HbA1c
Date:11/6/2008

- New labeling reinforces strong safety profile of Ranexa -

- Conference call scheduled for 8:00 a.m. ET/5:00 a.m. PT -

PALO ALTO, Calif., Nov. 6 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX) announced today that the U.S. Food and Drug Administration (FDA) has approved a new, first line indication for Ranexa(R) (ranolazine extended-release tablets) for the treatment of chronic angina. The new labeling also provides information showing that Ranexa reduced arrhythmias including ventricular arrhythmias, new onset atrial fibrillation and a potentially dangerous slow heartbeat known as bradycardia in patients with coronary artery disease. In addition, the new labeling states that Ranexa reduces hemoglobin A1c (HbA1c) in patients with diabetes.

According to the revised labeling, Ranexa is indicated for the treatment of chronic angina and may be used alone or in combination with traditional therapies for chronic angina, such as beta blockers, calcium channel blockers and nitrates, and common cardio-protective treatments for cardiovascular disease such as anti-platelet therapy, lipid-lowering therapy, ACE inhibitors and angiotensin receptor blockers.

Ranexa may now be used as part of an optimal medical therapy regimen for chronic angina patients, regardless of whether or not they receive a stent or other medical intervention. Ranexa does not reduce heart rate or blood pressure and, unlike long acting nitrates, Ranexa can be prescribed for patients taking oral erectile dysfunction treatments.

"This important FDA action allows the benefits of Ranexa to be extended to more patients. The new labeling clearly describes the substantial proven safety and efficacy of Ranexa for the treatment of chro
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. FDA Approves Additional Indication for Norditropin(R) for Small for Gestational Age (SGA) in Children
2. FDA Approves Durameds LoSEASONIQUE(R) Oral Contraceptive
3. FDA Approves Astellas Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia
4. FDA Approves Orphan Drug Status for Revolutionary Cancer Drug for Children
5. FDA Approves AstraZenecas SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania
6. FDA Approves Fougeras Clotrimazole Cream USP 1%
7. FDA Approves ALOXI(R) (Palonosetron HCl) Capsules for Prevention of Acute Chemotherapy-induced Nausea and Vomiting
8. USDA Approves Syngenta and John Deere for Broadened Biotechnology Endorsement for Corn Crop Insurance
9. Signalife Board Approves Merger
10. FDA Approves EOVIST(R) to Detect and Characterize Focal Liver Lesions
11. FDA Approves Abbotts XIENCE(TM) V Drug Eluting Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... BUFFALO, N.Y. , May 22, 2013 /PRNewswire/ ... exclusive license for a patent pending novel genomic ... a molecular diagnostic test that could help in ... (NEPC) prostate cancer.  Neuroendocrine prostate ... adenocarcinoma (PCA) that can arise de novo, but ...
(Date:5/22/2013)... 2013 AudioNotch is ... tinnitus treatment. AudioNotch is pleased to announce a ... locations in both British Columbia and Alberta, Destination ... hearing services. AudioNotch's tinnitus treatment program is now ... a Destination Hearing clinic, patients have the detection ...
(Date:5/22/2013)... 2013 A recent study from researchers ... to find that those who took probiotics were able to ... the study showed that in extreme heat conditions, probiotics were ... adult acne treatment explains what this new discovery ... help their skin condition. , While researchers tote the ...
(Date:5/21/2013)... , May 21, 2013  The Lindsley F. Kimball ... that it is a Grand Challenges Explorations winner, ... Foundation .  Dr. Sara Lustigman , Head ... global health and development research project, titled Innovative 3-D ...  These worms are needed to screen drugs to help eliminate ...
Breaking Biology Technology:Empire Genomics Licenses Novel DNA Biomarker for Use in Diagnosing and Creating a Companion Diagnostic Test for Neuroendocrine Prostate Cancer 2AudioNotch Tinnitus Treatment Launches Partnership With Destination Hearing 2Adult Acne Treatment, Probiotic Action Shares Insight on New Findings Between Probiotics and Heat Tolerance, and What It Means for Acne Sufferers 2New York Blood Center's Research Institute Receives Grand Challenges Explorations Grant For Groundbreaking Research in Global Health and Development 2New York Blood Center's Research Institute Receives Grand Challenges Explorations Grant For Groundbreaking Research in Global Health and Development 3
... 2010 Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ) ... Cap Conference in Las Vegas, Nevada on Tuesday, November 16, ... Alex Casdin, vice president, finance at Amylin Pharmaceuticals, will ... webcast live through the "Investors" section of Amylin,s corporate website ...
... Cardium Therapeutics (NYSE Amex: CXM ) today ... ended September 30, 2010.  Highlights of the quarter and ... of Cardium,s MedPodium product line, a portfolio of premium ... aesthetics designed to promote and manage personal health.  The ...
... ... ... ... are keyed by longUrl, so we need to grab the first one. for (var r in data.results) { first_result ...
Cached Biology Technology:Cardium Reports on Third Quarter 2010 Financial Results and Recent Developments 2Cardium Reports on Third Quarter 2010 Financial Results and Recent Developments 3Cardium Reports on Third Quarter 2010 Financial Results and Recent Developments 4Cardium Reports on Third Quarter 2010 Financial Results and Recent Developments 5Cardium Reports on Third Quarter 2010 Financial Results and Recent Developments 6Cardium Reports on Third Quarter 2010 Financial Results and Recent Developments 7Cardium Reports on Third Quarter 2010 Financial Results and Recent Developments 8Cardium Reports on Third Quarter 2010 Financial Results and Recent Developments 9Biovista Announces a Drug Repositioning Collaboration With Pfizer 2Biovista Announces a Drug Repositioning Collaboration With Pfizer 3Biovista Announces a Drug Repositioning Collaboration With Pfizer 4Biovista Announces a Drug Repositioning Collaboration With Pfizer 5Biovista Announces a Drug Repositioning Collaboration With Pfizer 6Biovista Announces a Drug Repositioning Collaboration With Pfizer 7Biovista Announces a Drug Repositioning Collaboration With Pfizer 8
(Date:5/21/2013)... method for delivering molecules into single, targeted cells ... technique could find applications in drug delivery, cell ... a technique used to deliver molecules into ... that are caused by exposing them to electric ... cell transfection. (Cell transfection is the introduction of ...
(Date:5/21/2013)... in shape is an uphill battle? Try staying fit ... weightlessness withers muscle and bone. , That,s the challenge ... with a new three-year, $1.2 million grant from NASA. ... during multiyear exploratory missions. , "You could give astronauts ... can,t get them to stick to it, it isn,t ...
(Date:5/21/2013)... ANDOVER, Mass. , May 21, 2013 ... that CX50 xMATRIX, the world,s first portable ultrasound with ... Intracardiac Echo (ICE) capability. The CX50 xMATRIX with available ... Paris at the EuroPCR, official ... (EAPCI), May 21-24. Since its launch in ...
Breaking Biology News(10 mins):Single-cell transfection tool enables added control for biological studies 2Fueling fitness on the final frontier 2Philips CX50 xMATRIX now offers world-class interventional and diagnostic features on single portable system 2
... Two distinguished Brandeis researchers, whose long-standing collaboration led ... biological clock and its role in circadian rhythms, ... that nation,s foremost international scientific honor. Michael ... Neuroscience and director of the Brandeis, National Center ...
... NC A growing body of research shows that birds ... noise, such as the din of traffic or the hum ... many animals also pollinate plants or eat or disperse their ... finds a new study. In cases where noise has ...
... In a surprising result, Michigan State University researchers ... found that mice on a calorie-restricted diet were more ... bacterial pathogen in the colon. While research ... bowel diseases such as colitis, the study results revealed ...
Cached Biology News:Brandeis scientists win prestigious prize for circadian rhythms research 2Brandeis scientists win prestigious prize for circadian rhythms research 3Brandeis scientists win prestigious prize for circadian rhythms research 4Not just for the birds: Man-made noise has ripple effects on plants, too 2Not just for the birds: Man-made noise has ripple effects on plants, too 3Low-calorie diet may be harmful for bowel disease patients 2
... The PROTEAN II XL cell, wide format, is ... 18.5 x 20 cm gels and requires 1.2 L ... basic unit and the 2.0 mm IPG conversion kit, ... gels and includes 2 sets of IPG clamps, 2 ...
... cocktail is tailored to highly ... of rat spleen cells. Cells ... (or compatible 0.5 Tesla) immunomagnetic ... cell content of the enriched ...
... is tailored to efficiently deplete ... of non-human primate (Rhesus monkey) ... the StemSep (or compatible 0.5 ... achieving a 2.6 Log depletion ...
... cocktail is tailored to highly ... suspensions of non-human primate (Rhesus ... using the StemSep compatible 0.5 ... The CD4+ T cell content ...
Biology Products: